Oops. Meant to say Phase 1 and 2 trials combined
"It is extremely well tolerated by patients, with safety data now exceeding 2700 patient years." That comment is referring to patient years of patients treated with apabetalone. I don't have time to calculate how many apabetalone patient years were in the previous Phase 1/2 trials, but I will spit-ball that no more than 1000 patients were treated with apabetalone in past Phase 1 and 2 trials combined for no longer than 6 months, which would be 500 patient years. This 500 is likely an over-estimate. So this crude estimate suggests that Phase 3 BETonMACE has at least 2200 apabetalone patient years.